Publications by authors named "W Barchuk"
Article Synopsis
- - Noninfectious uveitis is a major cause of vision loss and there is a need for better treatment options, prompting the investigation of filgotinib, a JAK1 inhibitor, for this condition.
- - The HUMBOLDT trial was a phase 2 study involving 74 participants, aged 18 and older, with active noninfectious uveitis, comparing filgotinib to a placebo over 52 weeks.
- - Results showed that 37.5% of those on filgotinib experienced treatment failure by week 24, significantly lower than the 67.6% for placebo, indicating that filgotinib may be an effective option for treating this illness.
Article Synopsis
- This phase 1b study assessed the safety and effectiveness of cilofexor, a drug targeting farnesoid X receptors, in patients with compensated cirrhosis caused by primary sclerosing cholangitis over 12 weeks.
- Patients received increasing doses of cilofexor, and while most reported side effects like pruritus and fatigue, there were no serious adverse events.
- Results showed significant improvements in liver function markers, indicating that cilofexor may help manage cholestasis in these patients.
Background: Novel noninvasive predictors of disease severity and prognosis in primary sclerosing cholangitis (PSC) are needed. This study evaluated the ability of extracellular matrix remodeling markers to diagnose fibrosis stage and predict PSC-related fibrosis progression and clinical events.
Methods: Liver histology and serum markers of collagen formation (propeptide of type III collagen [Pro-C3], propeptide of type IV collagen, propeptide of type V collagen), collagen degradation (type III collagen matrix metalloproteinase degradation product and type IV collagen matrix metalloproteinase degradation product), and fibrosis (enhanced liver fibrosis [ELF] score and its components [metalloproteinase-1, type III procollagen, hyaluronic acid]) were assessed in samples from baseline to week 96 in patients with PSC enrolled in a study evaluating simtuzumab (NCT01672853).
Cilofexor is a nonsteroidal farnesoid X receptor agonist being developed in combination with firsocostat/semaglutide for the treatment of nonalcoholic steatohepatitis. This phase 1 study evaluated the effects of food and acid-reducing agents (ARAs) on the pharmacokinetics of cilofexor (100- or 30-mg fixed-dose combination with firsocostat) in healthy participants. Cohorts 1 (n = 20, 100 mg) and 2 (n = 30, 30 mg) followed a 3-period, 2-sequence crossover design and evaluated effects of light-fat and high-fat meals.
View Article and Find Full Text PDFObjectives: To assess the effects of filgotinib on inflammatory and structural changes at various spinal locations, based on MRI measures in patients with active AS in the TORTUGA trial.
Methods: In the TORTUGA trial, patients with AS received filgotinib 200 mg (n = 58) or placebo (n = 58) once daily for 12 weeks. In this post hoc analysis, spine MRIs were evaluated using the Canada-Denmark (CANDEN) MRI scoring system to assess changes from baseline to week 12 in total spine and subscores for inflammation, fat, erosion and new bone formation (NBF) at various anatomical locations.